BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37252612)

  • 1. Optimizing COVID-19 Vaccination Strategy in Pediatric Kidney Transplant Recipients: Humoral and Cellular Response to SARS-CoV-2 mRNA Vaccination.
    Nel I; Parmentier C; Dehoux L; Minier M; Duneton C; Charbit M; Baudouin V; Bidet P; Carol A; Cheyssac E; Delbet JD; Guérin-El Khourouj V; Louillet F; Ulinski T; Delaugerre C; Carcelain G; Hogan J
    Transpl Int; 2023; 36():11153. PubMed ID: 37252612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
    Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
    Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response and live-virus neutralization of the SARS-CoV-2 omicron (BA.1) variant after COVID-19 mRNA vaccination in children and young adults with chronic kidney disease.
    Stich M; Di Cristanziano V; Tönshoff B; Weber LT; Dötsch J; Rammer MT; Rieger S; Heger E; Garbade SF; Burgmaier K; Benning L; Speer C; Habbig S; Haumann S
    Pediatr Nephrol; 2023 Jun; 38(6):1935-1948. PubMed ID: 36409368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Correlation Between Responders and Non-Responders to the Second Coronavirus Disease Vaccination In Kidney Transplant Recipients: A Retrospective Single-Center Cohort Study.
    Matsunami M; Suzuki T; Sugihara S; Toishi T; Nagaoka K; Fukuda J; Ohara M; Takanashi Y; Ochi A; Yashima J; Kuji H; Matsue K
    Transplant Proc; 2022; 54(6):1483-1488. PubMed ID: 35868872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
    Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
    J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low switched memory B cells are associated with no humoral response after SARS-CoV-2 vaccine boosters in kidney transplant recipients.
    Seija M; García-Luna J; Rammauro F; Brugnini A; Trías N; Astesiano R; Santiago J; Orihuela N; Zulberti C; Machado D; Recalde C; Yandián F; Guerisoli A; Noboa J; Orihuela S; Curi L; Bugstaller E; Noboa O; Nin M; Bianchi S; Tiscornia A; Lens D
    Front Immunol; 2023; 14():1202630. PubMed ID: 37942335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Response to Third and Fourth COVID-19 Vaccination in Hemodialysis Patients and Kidney Transplant Recipients.
    Affeldt P; Koehler FC; Brensing KA; Gies M; Platen E; Adam V; Butt L; Grundmann F; Heger E; Hinrichs S; Kalisch N; Oehm S; Steger G; Wirtz M; Benzing T; Stippel D; Klein F; Kurschat C; Müller RU; Di Cristanziano V
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral response after a third and fourth dose of mRNA-based SARS-CoV-2 vaccine in previously seronegative kidney transplant recipients.
    Brandstetter C; Haller MC; Berger JM; Kerschner H; Apfalter P; Cejka D
    Wien Klin Wochenschr; 2022 Dec; 134(23-24):815-821. PubMed ID: 36326920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
    Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
    Front Immunol; 2022; 13():876533. PubMed ID: 35711413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of one and two booster doses of SARS-CoV-2 mRNA vaccines in kidney transplant recipients: A randomized clinical trial.
    Drenko P; Kacer M; Kielberger L; Vlas T; Topolcan O; Kucera R; Reischig T
    Transpl Infect Dis; 2023 Oct; 25(5):e14150. PubMed ID: 37724748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic.
    Reischig T; Kacer M; Vlas T; Drenko P; Kielberger L; Machova J; Topolcan O; Kucera R; Kormunda S
    Am J Transplant; 2022 Mar; 22(3):801-812. PubMed ID: 34860470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients.
    Bertrand D; Hamzaoui M; Lemée V; Lamulle J; Hanoy M; Laurent C; Lebourg L; Etienne I; Lemoine M; Le Roy F; Nezam D; Plantier JC; Boyer O; Guerrot D; Candon S
    J Am Soc Nephrol; 2021 Sep; 32(9):2147-2152. PubMed ID: 34112706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral Response After SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Role of Immunosuppression Therapy.
    López V; Polo C; Schuldt R; Vázquez T; Gutiérrez-Vílchez E; Moliz C; Hernández D
    Transplant Proc; 2022 Nov; 54(9):2454-2456. PubMed ID: 36273957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
    Kemlin D; Gemander N; Depickère S; Olislagers V; Georges D; Waegemans A; Pannus P; Lemy A; Goossens ME; Desombere I; Michiels J; Vandevenne M; Heyndrickx L; Ariën KK; Matagne A; Ackerman ME; Le Moine A; Marchant A
    Am J Transplant; 2023 May; 23(5):649-658. PubMed ID: 36773936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.